Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate Cancer

Phase 2 Completed 94 enrolled Bristol-Myers Squibb

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to learn if men with metastatic prostate cancer and rising Prostate Specific Antigen (PSA), who have been surgically castrated or are undergoing androgen deprivation with Luteinizing Hormone Releasing Hormone (LHRH) treatment, respond to dasatinib. The safety of this treatment will also be studied.

Timeline

Start: 2007-01
Primary completion: 2008-12
Completion: 2010-10

Publications

Background Yu EY, Wilding G, Posadas E, Gross M, Culine S, Massard C, Morris MJ, Hudes G, Calabro F, Cheng S, Trudel GC, Paliwal P, Sternberg CN. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res. 2009 Dec 1;15(23):7421-8. doi: 10.1158/1078-0432.CCR-09-1691. Epub 2009 Nov 17.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	dasatinib anhydrous	Small molecule	70 mg	Oral
Subject	dasatinib anhydrous	Small molecule	100 mg	Oral

Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate Cancer

Summary

Timeline

Publications

Drugs

Indications